MX2020003578A - Sal de edaravone. - Google Patents

Sal de edaravone.

Info

Publication number
MX2020003578A
MX2020003578A MX2020003578A MX2020003578A MX2020003578A MX 2020003578 A MX2020003578 A MX 2020003578A MX 2020003578 A MX2020003578 A MX 2020003578A MX 2020003578 A MX2020003578 A MX 2020003578A MX 2020003578 A MX2020003578 A MX 2020003578A
Authority
MX
Mexico
Prior art keywords
edaravone salt
edaravone
salt
empty
Prior art date
Application number
MX2020003578A
Other languages
English (en)
Inventor
Casares Ana Fernandez
Sytske Hyke Moolenaar
Der Geest Ronald Van
Original Assignee
Treeway Tw001 B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeway Tw001 B V filed Critical Treeway Tw001 B V
Publication of MX2020003578A publication Critical patent/MX2020003578A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una sal de 3-metil-1-fenil-2-pirazolin-5 -ona (edaravone), en la que la sal es napadisilato de 3-metil-1-fenil-2-pirazolin-5-ona o hemi-napadisilato de 3-metil-1-fenil-2-pirazolin-5-ona. Estas sales de napadisilato de edaravone son fáciles de fabricar y se disuelven más rápidamente en agua que la base de edaravone libre. Además, las sales de edaravone de la presente invención son muy estables y fáciles de manejar. La invención también se refiere a una composición farmacéutica que comprende la sal de edaravone mencionada anteriormente y a un procedimiento de preparación de dicha sal de edaravone.
MX2020003578A 2017-10-13 2018-10-12 Sal de edaravone. MX2020003578A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17196400 2017-10-13
PCT/EP2018/077918 WO2019073052A1 (en) 2017-10-13 2018-10-12 EDARAVONE SALT

Publications (1)

Publication Number Publication Date
MX2020003578A true MX2020003578A (es) 2020-07-22

Family

ID=60083871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003578A MX2020003578A (es) 2017-10-13 2018-10-12 Sal de edaravone.

Country Status (8)

Country Link
US (1) US11117868B2 (es)
EP (1) EP3694839B1 (es)
JP (1) JP7152122B2 (es)
KR (1) KR20200071090A (es)
CN (1) CN111465597B (es)
ES (1) ES2928785T3 (es)
MX (1) MX2020003578A (es)
WO (1) WO2019073052A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210154009A (ko) 2020-06-11 2021-12-20 현대모비스 주식회사 자동차용 램프 및 카메라 조립체
GB202103807D0 (en) 2021-03-18 2021-05-05 Johnson Matthey Plc A crystalline salt of edaravone, processes for the preparation and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2042663A1 (de) * 1970-08-28 1972-03-02 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches Trockenkopierverfahren
JPH07121861B2 (ja) * 1986-11-25 1995-12-25 三菱化学株式会社 ３−メチル−１−フエニル−２−ピラゾロン−５−オンを含有する安定な注射剤
CA2460141C (en) 2001-09-14 2012-01-10 Mitsubishi Pharma Corporation Drugs comprising combination of antithrombotic agent with pyrazolone derivative
JP4746856B2 (ja) 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
GB0612420D0 (en) 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
JP5373634B2 (ja) * 2007-02-07 2013-12-18 パルメイゲン・セラピューティクス・（シナジー）・リミテッド ムスカリンｍ３アンタゴニストのナパジシル酸塩
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2641900A1 (en) * 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN103483262A (zh) 2013-09-17 2014-01-01 天津市嵩锐医药科技有限公司 稳定的依达拉奉三水化合物及其药物组合物

Also Published As

Publication number Publication date
JP2020536940A (ja) 2020-12-17
WO2019073052A1 (en) 2019-04-18
EP3694839A1 (en) 2020-08-19
CN111465597A (zh) 2020-07-28
CN111465597B (zh) 2023-08-25
US20200308120A1 (en) 2020-10-01
JP7152122B2 (ja) 2022-10-12
KR20200071090A (ko) 2020-06-18
US11117868B2 (en) 2021-09-14
ES2928785T3 (es) 2022-11-22
EP3694839B1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
MX2020003441A (es) Transmision de referencia de sondeo.
ZA202102549B (en) Substituted tolyl as fungicides
PH12020550546A1 (en) Dispenser having a cartridge holder
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
GB2565911B (en) Multiple diaphragm pump
MX2017000363A (es) Inhibicion de la via de notch.
MX2020003760A (es) Formulaciones de niraparib.
MX2020003712A (es) Union giratoria de pasaje multiple.
AU201714122S (en) Double diaphragm pump
MX2020004424A (es) Formulacion aerosolizable.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020003452A (es) Dispositivo de malla de alambre.
MX2020003649A (es) Elemento de seguridad optico.
MX2020003617A (es) Dispositivo de preparacion de cables.
MX2019015167A (es) Farmacos antivirales.
GB201702804D0 (en) An antimicrobial solution
MX2020003578A (es) Sal de edaravone.
MX2020004245A (es) Estabilizador mejorado para poliamidas.
MX2020004272A (es) Cartucho configurado para formar una parte de una pezonera y una pezonera.
MX2020002908A (es) Composicion acuosa de polimeros.
GB2587987B (en) Host-biome interactions
MX2020003440A (es) Red de seguridad.
MX2020004048A (es) Formas cristalinas de lenalidomida.
MX2020004282A (es) Embalaje del producto.
ZA201803737B (en) Holster